Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: A randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1776-1786

  Lal, Ritu ^a   Sukbuntherng, Juthamas ^a   Luo, Wendy ^a   Chen, Dan ^a   Vu, Amanda ^b   Tovera, James ^a   Cundy, Kenneth C ^a  

^a XenoPort Inc   (United States)

^b Stiefel Laboratories Inc   (United States)

Author keywords

gabapentin; gabapentin enacarbil; GSK1838262; pharmacokinetics; XP13512

Indexed keywords

GABAPENTIN; GABAPENTIN ENACARBIL; PLACEBO;

ADULT; APPLICATION SITE DERMATITIS; AREA UNDER THE CURVE; ARTICLE; BALANCE DISORDER; BLOOD PRESSURE; BLOOD SAMPLING; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUNK SENSATION; ELECTROCARDIOGRAM; EUPHORIA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PSYCHOMOTOR RETARDATION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VERTIGO; VITAL SIGN; VOMITING;

ADOLESCENT; ADULT; ANALGESICS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBAMATES; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PRODRUGS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 72149086940     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.07.026     Document Type: Article

References (23)

1. Beydoun A., Uthman B.M., and Sackellares J.C. Gabapentin: Pharmacokinetics, efficacy, and safety. Clin Neuropharmacol. 18 (1995) 469-481
2. Rice A.S., Maton S., and Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 94 (2001) 215-224
3. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 280 (1998) 1837-1842
4. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 335 (1990) 1114-1117
5. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology 43 (1993) 2292-2298
6. Anhut H., Ashman P., Feuerstein T.J., et al., International Gabapentin Study Group. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled study. Epilepsia 35 (1994) 795-801
7. Appleton R., Fichtner K., LaMoreaux L., et al., Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicentre, double-blind, placebo-controlled study. Epilepsia 40 (1999) 1147-1154
8. McLean M.J. Gabapentin in the management of convulsive disorders. Epilepsia 40 Suppl 6 (1999) S39-S50 discussion
9. McLean M.J. Gabapentin in the management of convulsive disorders. Epilepsia 40 Suppl 6 (1999) S73-S74
10. Kriel R.L., Birnbaum A.K., Cloyd J.C., et al. Failure of absorption of gabapentin after rectal administration. Epilepsia 38 (1997) 1242-1244
11. Stevenson C.M., Kim J., and Fleisher D. Colonic absorption of antiepileptic agents. Epilepsia 38 (1997) 63-67
12. Stewart B.H., Kugler A.R., Thompson P.R., and Bockbrader H.N. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 10 (1993) 276-281
13. Gidal B.E., DeCerce J., Bockbrader H.N., et al. Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31 (1998) 91-99
14. McLean M.J. Gabapentin. Epilepsia 36 Suppl 2 (1995) S73-S86
15. Gidal B.E., Radulovic L.L., Kruger S., et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 40 (2000) 123-127
16. Cundy K.C., Annamalai T., Bu L., et al. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabap-entin in rats and monkeys. J Pharmacol Exp Ther. 311 (2004) 324-333
17. Cundy K.C., Sastry S., Luo W., et al. Clinical pharmacokinetics of XP13512, a novel transported pro-drug of gabapentin. J Clin Pharmacol. 48 (2008) 1378-1388
18. Cundy K.C., Branch R., Chernov-Rogan T., et al. XP13512 ([(alpha-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 311 (2004) 315-323
19. Kushida C.A., Becker P.M., Ellenbogen A.L., et al., XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 72 (2009) 439-446
20. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16 (1976) 31-41
21. World Medical Association (WMA). WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 Revision. http://www.wma.net/e/policy/b3.htm Accessed June 15, 2009
22. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed (1982), M. Dekker, New York, NY
23. Smith B.P., Vandenhende F.R., De-Sante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 17 (2000) 1278-1283